Influenza A virus subtype H7N3
Influenza A virus subtype H7N3 is a subtype of the Influenza A virus that can cause illness in humans and many other animal species. A bird-adapted strain of H7N3 is endemic in domestic poultry in North America. This is of particular concern because H7, along with H5, is a subtype that has caused human pandemics in the past.
History[edit]
The H7N3 subtype was first isolated in turkeys in England in 1963. Since then, outbreaks have been reported in various parts of the world, including Canada, the United States, Italy, and Mexico. The most notable outbreak occurred in British Columbia, Canada in 2004, where it resulted in the culling of 17 million birds.
Transmission[edit]
H7N3 is primarily spread through direct contact with fecal matter from infected birds, or through contact with surfaces contaminated with this fecal matter. Human infections are rare, but have been associated with exposure to infected poultry or contaminated environments.
Symptoms[edit]
In birds, symptoms of H7N3 infection can range from mild illness to severe disease, which can result in death. In humans, symptoms can include conjunctivitis and mild upper respiratory symptoms, with potential complications such as pneumonia and acute respiratory distress syndrome.
Prevention and Control[edit]
Prevention and control measures for H7N3 include surveillance, rapid diagnosis, culling of infected birds, and vaccination of poultry. In humans, antiviral drugs can be used for treatment and prophylaxis.
See Also[edit]
| Influenza | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
-
Avian influenza in the heart of a turkey
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian